Capsid engineering is highlighted as an important aspect of ocular gene therapy platform design in AMD. The abstract does not specify particular engineered capsids or performance outcomes.
First-pass extracted concept
capsid engineering
Candidate: concept label3 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
Evidence Snippets
This review summarises the biological rationale, vector platforms, and delivery routes relevant to AMD, with emphasis on adeno-associated virus (AAV) systems, capsid engineering, and compartment-specific administration.
Recent advances in capsid engineering, tissue-specific promoters, and delivery strategies have enhanced podocyte targeting while minimizing off-target effects.
the delivery of genome editors to the outer retina remains suboptimal, prompting intensive efforts in capsid engineering and the development of non-viral delivery systems.
Supporting Sources
Linked Claims
The review emphasizes adeno-associated virus systems, capsid engineering, and compartment-specific administration routes for AMD gene therapy.
Quoted textsource-backed
This review summarises the biological rationale, vector platforms, and delivery routes relevant to AMD, with emphasis on adeno-associated virus (AAV) systems, capsid engineering, and compartment-specific administration (intravitreal, subretinal, and suprachoroidal).
Advances in capsid engineering, tissue-specific promoters, and delivery strategies have enhanced podocyte targeting while minimizing off-target effects.
Delivery of genome editors to the outer retina remains suboptimal, motivating capsid engineering and development of non-viral delivery systems.
Quoted textsource-backed
the delivery of genome editors to the outer retina remains suboptimal, prompting intensive efforts in capsid engineering and the development of non-viral delivery systems